Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 111

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 111
---
 From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and sales of our drugs, if approved. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in operating results from one period to the next. In addition, our measures compensation cost for stock-based awards made to employees, directors and non-employee consultants based on the fair value of the award on the grant date and we recognize the cost as an expense over the requisite service period, as applicable. Because the variables that we uses as a basis for valuing stock-based awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. Furthermore, operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:

| ● | delays in the commencement, enrollment and the timing of clinical testing for our product candidates; |

| ● | the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; |

| ● | any delays in regulatory review and approval of product candidates in clinical development; |

| ● | the timing and cost of, and level of investment in, R&D activities relating to our product candidates, which may change from time to time; |

| ● | the cost of manufacturing our product candidates, which may vary depending on FDA guidelines and requirements, and the quantity of production; |

| ● | Our ability to obtain additional funding to develop product candidates; |

| ● | expenditures that our will or may incur to acquire or develop additional product candidates and technologies; |

| ● | the level of demand for our product candidates, should they receive approval, which may vary significantly; |

| ● | potential side effects of our product candidates that could delay or prevent commercialization or cause an approved drug to be taken off the market; |

| ● | the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our product candidates, if approved; |

61

| ● | Our dependency on third-party manufacturers to supply or manufacture our product candidates; |

|